Health Sciences

Two widely used targeted therapy drugs— approved by the FDA for use in metastatic kidney cancer —are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to new results to be presented by a researcher at the University of Pennsylvania’s 

The topical eczema medicine pimecrolimus appears unlikely to be associated with an increased risk of cancer in children, based on a group of children who were followed for 10 years, according to study published online this week in JAMA Dermatology.

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsy

A leader in the rapidly changing field of epigenetics, Shelley L.

Although wearable devices have received significant attention for their ability to track an individual’s physical activity, most smartphone applications are just as accurate, according to a new research letter in JAMA.

Experts have warned for years that insufficient sleep can lead to weight gain.

Stating that sleep is an essential biological process seems as obvious as saying that the sun rises every morning. Yet, researchers' understanding of the molecular mechanisms underlying the effects of sleep loss is still in its earliest stages.

Doctors treating patients battling both HIV and tuberculosis (TB)—many of whom live in Africa—are faced with the decision when to start those patients on antiretroviral therapy (ART) while they are being treated with antibiotics for active TB disease. 

If you were about to enter a crowded subway during flu season, packed with people sneezing and coughing, wouldn’t it be helpful if your immune system recognized the potentially risky situation and bolstered its defenses upon stepping into the train?

Penn Medicine researchers have begun a new immunotherapy trial with the “checkpoint inhibitor” known as pembrolizumab in patients with oligometastatic lung cancer—a state characterized by a few metastases in a confined area—who have completed conventional treatments and are considered free of active disease but remain at a high risk for recurrence.